Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Genomic profiling may reveal new drug targets in urothelial carcinoma

2015 Genitourinary Cancers Symposium

26 - 28 Feb 2015

Published: 27 Feb 2015

Views: 4556

Rating:

Save

Dr Jeffrey Ross - Albany Medical College, Albany, USA

Urinary bladder urothelial carcinoma is a devastating disease with extremely limited treatment options - how can we find new drug targets for it?

Dr Jeffrey Ross talks to ecancertv at ASCO GU 2015 about his work on the genomic profiling of bladder carcinoma, looking for genetic alterations that will give clues for future treatments.

Related Videos

Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective...

Dr Chiara Mercinelli - San Raffaele Scientific Institute, Milan, Italy

Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective perioperative strategy for MIBC ( Dr Chiara Mercinelli - San Raffaele Scientific Institute, Milan, Italy )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

Cabozantinib and atezolizumab show more efficacy compared to second NHT in...

Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA

Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC ( Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA )

A biomarker led approach to bladder cancer

Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...

A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )

Molecular profiling in prostate cancer: key challenges for clinical...

Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain

Molecular profiling in prostate cancer: key challenges for clinical implementation ( Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain )

Updates in prostate cancer from ESMO 2022

Prof Eleni Efstathiou, Prof Gerhardt Attard and Prof Boris Hadaschik

Updates in prostate cancer from ESMO 2022 ( Prof Eleni Efstathiou, Prof Gerhardt Attard and Prof Boris Hadaschik )

Latest in mRCC from ESMO 2022

Dr Javier Puente, Dr Bernard Escudier, Prof Viktor Grünwald and Prof Stéphane...

Latest in mRCC from ESMO 2022 ( Dr Javier Puente, Dr Bernard Escudier, Prof Viktor Grünwald and Prof Stéphane Oudard )

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike...

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer ( Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann )

Bladder cancer: Current state and future directions in treatment

Prof Jorge Garcia - GU Medical Oncology Program, UH Seidman Cancer Center, Case...

Bladder cancer: Current state and future directions in treatment ( Prof Jorge Garcia - GU Medical Oncology Program, UH Seidman Cancer Center, Case Western Reserve University, Cleveland, USA )

More from ecancer